Skip to main content
Top
Published in: Drug Safety 10/2007

01-10-2007 | Review Article

Corticosteroid-Induced Adverse Events in Adults

Frequency, Screening and Prevention

Authors: Dr Laurence Fardet, Abdulrhaman Kassar, Jean Cabane, Antoine Flahault

Published in: Drug Safety | Issue 10/2007

Login to get access

Abstract

Corticosteroids represent the most important and frequently used class of anti-inflammatory drugs and are the reference therapy for numerous neoplastic, immunological and allergic diseases. However, their substantial efficacy is often counter-balanced by multiple adverse events. These corticosteroid-induced adverse events represent a broad clinical and biological spectrum from mild irritability to severe and life-threatening adrenal insufficiency or cardiovascular events.
The purpose of this article is to provide an overview of the available data regarding the frequency, screening and prevention of the adverse events observed in adults during systemic corticosteroid therapy (topically administered corticosteroids are outside the remit of this review). These include clinical (i.e. adipose tissue redistribution, hypertension, cardiovascular risk, osteoporosis, myopathy, peptic ulcer, adrenal insufficiency, infections, mood disorders, ophthalmological disorders, skin disorders, menstrual disorders, aseptic necrosis, pancreatitis) and biological (i.e. electrolytes homeostasis, diabetogenesis, dyslipidaemia) events. Lastly, data about the prescription of corticosteroids during pregnancy are provided. This review underscores the absence of data on many of these adverse events (e.g. lipodystrophy, dyslipidaemia).
Our intent is to present to practitioners data that can be used in a practical way to both screen and prevent most of the adverse events observed during systemic corticosteroid therapy.
Literature
1.
go back to reference Walsh LJ, Wong CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996 Aug 10; 313(7053): 344–6PubMedCrossRef Walsh LJ, Wong CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996 Aug 10; 313(7053): 344–6PubMedCrossRef
2.
go back to reference van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM 2000 Feb; 93(2): 105–11PubMedCrossRef van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM 2000 Feb; 93(2): 105–11PubMedCrossRef
3.
go back to reference Smyllie HC, Connolly CK. Incidence of serious complications of corticosteroid therapy in respiratory disease: a retrospective survey of patients in the Brompton hospital. Thorax 1968 Nov; 23(6): 571–81PubMedCrossRef Smyllie HC, Connolly CK. Incidence of serious complications of corticosteroid therapy in respiratory disease: a retrospective survey of patients in the Brompton hospital. Thorax 1968 Nov; 23(6): 571–81PubMedCrossRef
4.
go back to reference Quaade F. Undesirable effects of glucocorticoids. Acta Med Scand Suppl 1969; 500: 77–80PubMed Quaade F. Undesirable effects of glucocorticoids. Acta Med Scand Suppl 1969; 500: 77–80PubMed
5.
go back to reference McKeage K, Goa KL. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn’s disease in adults. Drugs 2002; 62(15): 2263–82PubMedCrossRef McKeage K, Goa KL. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn’s disease in adults. Drugs 2002; 62(15): 2263–82PubMedCrossRef
6.
go back to reference Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001 Jan 16; 134(2): 106–14PubMed Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001 Jan 16; 134(2): 106–14PubMed
7.
go back to reference van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002 Jan 1; 136(1): 1–12PubMed van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002 Jan 1; 136(1): 1–12PubMed
8.
go back to reference Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005 Nov; 52(11): 3371–80PubMedCrossRef Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005 Nov; 52(11): 3371–80PubMedCrossRef
9.
go back to reference Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004 Oct 5; 141(7): 493–500PubMed Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004 Oct 5; 141(7): 493–500PubMed
10.
go back to reference Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut 1997 Aug; 41(2): 209–14 Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut 1997 Aug; 41(2): 209–14
11.
go back to reference Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn’s disease. The 877 Israeli Budesonide Study Group. Gastroenterology 1998 Oct; 115(4): 835–40 Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn’s disease. The 877 Israeli Budesonide Study Group. Gastroenterology 1998 Oct; 115(4): 835–40
12.
go back to reference Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol 1972 Jun; 49(6): 329–36PubMedCrossRef Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol 1972 Jun; 49(6): 329–36PubMedCrossRef
13.
go back to reference Thomas TP. The complications of systemic corticosteroid therapy in the elderly: a retrospective study. Gerontology 1984; 30(1): 60–5PubMedCrossRef Thomas TP. The complications of systemic corticosteroid therapy in the elderly: a retrospective study. Gerontology 1984; 30(1): 60–5PubMedCrossRef
14.
go back to reference Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994 Feb; 96(2): 115–23PubMedCrossRef Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994 Feb; 96(2): 115–23PubMedCrossRef
15.
go back to reference Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001 Apr; 56(4): 279–84PubMedCrossRef Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001 Apr; 56(4): 279–84PubMedCrossRef
16.
go back to reference Rizzato G, Riboldi A, Imbimbo B, et al. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis. Respir Med 1997 Sep; 91(8): 449–60PubMedCrossRef Rizzato G, Riboldi A, Imbimbo B, et al. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis. Respir Med 1997 Sep; 91(8): 449–60PubMedCrossRef
17.
go back to reference Chibane S, Feldman-Billard S, Rossignol I, et al. Short-term tolerance of three days pulse methyprednisolone therapy: a prospective study in 146 patients [in French]. Rev Med Interne 2005 Jan; 26(1): 20–6PubMedCrossRef Chibane S, Feldman-Billard S, Rossignol I, et al. Short-term tolerance of three days pulse methyprednisolone therapy: a prospective study in 146 patients [in French]. Rev Med Interne 2005 Jan; 26(1): 20–6PubMedCrossRef
18.
go back to reference Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol 2007; 157(1): 142–8PubMedCrossRef Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol 2007; 157(1): 142–8PubMedCrossRef
19.
go back to reference Shubin H. Long term (five or more years) administration of corticosteroids in pulmonary diseases. Dis Chest 1965 Sep; 48(3): 287–90PubMedCrossRef Shubin H. Long term (five or more years) administration of corticosteroids in pulmonary diseases. Dis Chest 1965 Sep; 48(3): 287–90PubMedCrossRef
20.
go back to reference Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997 Oct; 40(10): 1873–8PubMedCrossRef Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997 Oct; 40(10): 1873–8PubMedCrossRef
21.
go back to reference Akerkar GA, Peppercorn MA, Hamel MB, et al. Corticosteroid-associated complications in elderly Crohn’s disease patients. Am J Gastroenterol 1997 Mar; 92(3): 461–4PubMed Akerkar GA, Peppercorn MA, Hamel MB, et al. Corticosteroid-associated complications in elderly Crohn’s disease patients. Am J Gastroenterol 1997 Mar; 92(3): 461–4PubMed
22.
go back to reference Covar RA, Leung DY, McCormick D, et al. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000 Oct; 106(4): 651–9PubMedCrossRef Covar RA, Leung DY, McCormick D, et al. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000 Oct; 106(4): 651–9PubMedCrossRef
23.
go back to reference Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003 Oct 15; 49(5): 703–8PubMedCrossRef Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003 Oct 15; 49(5): 703–8PubMedCrossRef
24.
go back to reference Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994 Dec; 236(6): 619–32PubMedCrossRef Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994 Dec; 236(6): 619–32PubMedCrossRef
25.
go back to reference Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002 Oct; 96(1): 23–43PubMedCrossRef Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002 Oct; 96(1): 23–43PubMedCrossRef
26.
go back to reference Fardet L, Cabane J, Lebbe C, et al. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol. Epub 2007 Jun 18 Fardet L, Cabane J, Lebbe C, et al. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol. Epub 2007 Jun 18
27.
go back to reference Stanbury RM, Graham EM. Systemic corticosteroid therapy: side effects and their management. Br J Ophthalmol 1998 Jun; 82(6): 704–8PubMedCrossRef Stanbury RM, Graham EM. Systemic corticosteroid therapy: side effects and their management. Br J Ophthalmol 1998 Jun; 82(6): 704–8PubMedCrossRef
28.
go back to reference Benet LZ, Frey FJ, Amend Jr WJ, et al. Endogenous and exogenous glucocorticoids in cushingoid patients. Drug Intell Clin Pharm 1982 Nov; 16(11): 863–8PubMed Benet LZ, Frey FJ, Amend Jr WJ, et al. Endogenous and exogenous glucocorticoids in cushingoid patients. Drug Intell Clin Pharm 1982 Nov; 16(11): 863–8PubMed
29.
go back to reference Bergrem H, Jervell J, Flatmark A. Prednisolone pharmacokinetics in cushingoid and non-cushingoid kidney transplant patients. Kidney Int 1985 Feb; 27(2): 459–64PubMedCrossRef Bergrem H, Jervell J, Flatmark A. Prednisolone pharmacokinetics in cushingoid and non-cushingoid kidney transplant patients. Kidney Int 1985 Feb; 27(2): 459–64PubMedCrossRef
30.
go back to reference Fardet L, Flahault A, Tiev KP, et al. Natural history of corticosteroid-induced lipodystrophy: a prospective study in 37 patients. Rev Med Interne. In press Fardet L, Flahault A, Tiev KP, et al. Natural history of corticosteroid-induced lipodystrophy: a prospective study in 37 patients. Rev Med Interne. In press
31.
go back to reference Fardet L, Cabane J, Kettaneh A, et al. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology (Oxford) 2007 Jul; 46(7): 1102–6CrossRef Fardet L, Cabane J, Kettaneh A, et al. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology (Oxford) 2007 Jul; 46(7): 1102–6CrossRef
32.
go back to reference Sato A, Funder JW, Okubo M, et al. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens 1995 Aug; 8(8): 823–8 Sato A, Funder JW, Okubo M, et al. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens 1995 Aug; 8(8): 823–8
33.
go back to reference Williamson PM, Kelly JJ, Whitworth JA. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl 1996 Dec; 14(5): S37–41PubMed Williamson PM, Kelly JJ, Whitworth JA. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl 1996 Dec; 14(5): S37–41PubMed
34.
go back to reference Kelly JJ, Mangos G, Williamson PM, et al. Cortisol and hypertension. Clin Exp Pharmacol Physiol Suppl 1998 Nov; 25: S51–6PubMedCrossRef Kelly JJ, Mangos G, Williamson PM, et al. Cortisol and hypertension. Clin Exp Pharmacol Physiol Suppl 1998 Nov; 25: S51–6PubMedCrossRef
35.
go back to reference Whitworth JA, Schyvens CG, Zhang Y, et al. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol 2001 Dec; 28(12): 993–6PubMedCrossRef Whitworth JA, Schyvens CG, Zhang Y, et al. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol 2001 Dec; 28(12): 993–6PubMedCrossRef
36.
go back to reference Whitworth JA, Gordon D, Andrews J, et al. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989 Jul; 7(7): 537–49PubMedCrossRef Whitworth JA, Gordon D, Andrews J, et al. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989 Jul; 7(7): 537–49PubMedCrossRef
37.
go back to reference Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989 May; 62(5): 375–91PubMed Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989 May; 62(5): 375–91PubMed
38.
go back to reference Whitworth JA, Kelly JJ. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Endocrinol Invest 1995 Jul–Aug; 18(7): 586–91PubMed Whitworth JA, Kelly JJ. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Endocrinol Invest 1995 Jul–Aug; 18(7): 586–91PubMed
39.
go back to reference Montrella-Waybill M, Clore JN, Schoolwerth AC, et al. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab 1991 May; 72(5): 1060–6PubMedCrossRef Montrella-Waybill M, Clore JN, Schoolwerth AC, et al. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab 1991 May; 72(5): 1060–6PubMedCrossRef
40.
go back to reference Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004 Aug; 90(8): 859–65PubMedCrossRef Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004 Aug; 90(8): 859–65PubMedCrossRef
41.
go back to reference Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004 Nov 16; 141(10): 764–70PubMed Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004 Nov 16; 141(10): 764–70PubMed
42.
go back to reference Erstad BL. Severe cardiovascular adverse effects in association with acute, high-dose corticosteroid administration. DICP 1989 Dec; 23(12): 1019–23PubMed Erstad BL. Severe cardiovascular adverse effects in association with acute, high-dose corticosteroid administration. DICP 1989 Dec; 23(12): 1019–23PubMed
43.
go back to reference Tvede N, Nielsen LP, Andersen V. Bradycardia after high-dose intravenous methylprednisolone therapy. Scand J Rheumatol 1986; 15(3): 302–4PubMedCrossRef Tvede N, Nielsen LP, Andersen V. Bradycardia after high-dose intravenous methylprednisolone therapy. Scand J Rheumatol 1986; 15(3): 302–4PubMedCrossRef
44.
go back to reference Fujimoto S, Kondoh H, Yamamoto Y, et al. Holter electrocardiogram monitoring in nephrotic patients during methylprednisolone pulse therapy. Am J Nephrol 1990; 10(3): 231–6PubMedCrossRef Fujimoto S, Kondoh H, Yamamoto Y, et al. Holter electrocardiogram monitoring in nephrotic patients during methylprednisolone pulse therapy. Am J Nephrol 1990; 10(3): 231–6PubMedCrossRef
45.
go back to reference Bonnotte B, Chauffert B, Martin F, et al. Side-effects of high-dose intravenous (pulse) methylprednisolone therapy cured by potassium infusion [letter]. Br J Rheumatol 1998 Jan; 37(1): 109PubMedCrossRef Bonnotte B, Chauffert B, Martin F, et al. Side-effects of high-dose intravenous (pulse) methylprednisolone therapy cured by potassium infusion [letter]. Br J Rheumatol 1998 Jan; 37(1): 109PubMedCrossRef
46.
go back to reference Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol 1986 Feb; 14 (2 Pt 1): 161–77PubMedCrossRef Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol 1986 Feb; 14 (2 Pt 1): 161–77PubMedCrossRef
47.
go back to reference van der Voort DJ, Geusens PP, Dinant GJ. A cross-sectional study of postmenopausal women found an association between osteoporosis and past gastric surgery or oral corticosteroids. J Clin Epidemiol 2004 May; 57(5): 533–8PubMedCrossRef van der Voort DJ, Geusens PP, Dinant GJ. A cross-sectional study of postmenopausal women found an association between osteoporosis and past gastric surgery or oral corticosteroids. J Clin Epidemiol 2004 May; 57(5): 533–8PubMedCrossRef
48.
go back to reference Goldstein MF, Fallon Jr JJ, Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest 1999 Dec; 116(6): 1733–49PubMedCrossRef Goldstein MF, Fallon Jr JJ, Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest 1999 Dec; 116(6): 1733–49PubMedCrossRef
49.
go back to reference Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003 Nov; 48(11): 3224–9PubMedCrossRef Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003 Nov; 48(11): 3224–9PubMedCrossRef
50.
go back to reference Hajiroussou VJ, Webley M. Prolonged low-dose corticosteroid therapy and osteoporosis in rheumatoid arthritis. Ann Rheum Dis 1984 Feb; 43(1): 24–7PubMedCrossRef Hajiroussou VJ, Webley M. Prolonged low-dose corticosteroid therapy and osteoporosis in rheumatoid arthritis. Ann Rheum Dis 1984 Feb; 43(1): 24–7PubMedCrossRef
51.
go back to reference Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991 Jun; 18(6): 804–8PubMed Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991 Jun; 18(6): 804–8PubMed
52.
go back to reference Pearce G, Ryan PF, Delmas PD, et al. The deleterious effects of low-dose corticosteroids on bone density in patients with 878 polymyalgia rheumatica. Br J Rheumatol 1998 Mar; 37(3): 292–9PubMedCrossRef Pearce G, Ryan PF, Delmas PD, et al. The deleterious effects of low-dose corticosteroids on bone density in patients with 878 polymyalgia rheumatica. Br J Rheumatol 1998 Mar; 37(3): 292–9PubMedCrossRef
53.
go back to reference LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990 Jan; 8(1): 39–51CrossRef LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990 Jan; 8(1): 39–51CrossRef
54.
go back to reference Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study. Ann Intern Med 1993 Nov 15; 119(10): 963–8PubMed Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study. Ann Intern Med 1993 Nov 15; 119(10): 963–8PubMed
55.
go back to reference Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corti-costeroid therapy and hip fracture. Ann Rheum Dis 1995 Jan; 54(1): 49–52PubMedCrossRef Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corti-costeroid therapy and hip fracture. Ann Rheum Dis 1995 Jan; 54(1): 49–52PubMedCrossRef
56.
go back to reference McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 Mar; 157 (3 Pt 1): 704–9PubMed McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 Mar; 157 (3 Pt 1): 704–9PubMed
57.
go back to reference Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983 Aug 4; 309(5): 265–8PubMedCrossRef Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983 Aug 4; 309(5): 265–8PubMedCrossRef
58.
go back to reference Kaji H, Yamauchi M, Chihara K, et al. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J 2006 Feb; 53(1): 27–34PubMedCrossRef Kaji H, Yamauchi M, Chihara K, et al. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J 2006 Feb; 53(1): 27–34PubMedCrossRef
59.
go back to reference Reid IR. Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab 2000 Jun; 14(2): 279–98PubMedCrossRef Reid IR. Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab 2000 Jun; 14(2): 279–98PubMedCrossRef
61.
go back to reference Bell R, Carr A, Thompson P. Managing corticosteroid induced osteoporosis in medical outpatients. J R Coll Physicians Lond 1997 Mar–Apr; 31(2): 158–61PubMed Bell R, Carr A, Thompson P. Managing corticosteroid induced osteoporosis in medical outpatients. J R Coll Physicians Lond 1997 Mar–Apr; 31(2): 158–61PubMed
62.
go back to reference Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; (2): CD000952 Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; (2): CD000952
63.
go back to reference Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000; (2): CD001347 Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000; (2): CD001347
64.
go back to reference Amin S, Lavalley MP, Simms RW, et al. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002 Aug; 17(8): 1512–26PubMedCrossRef Amin S, Lavalley MP, Simms RW, et al. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002 Aug; 17(8): 1512–26PubMedCrossRef
65.
go back to reference Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001 Jul; 44 (7): 1496–503 Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001 Jul; 44 (7): 1496–503
66.
go back to reference Yood RA, Harrold LR, Fish L, et al. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Archives Intern Med 2001 May 28; 161(10): 1322–7CrossRef Yood RA, Harrold LR, Fish L, et al. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Archives Intern Med 2001 May 28; 161(10): 1322–7CrossRef
67.
go back to reference Hougardy DM, Peterson GM, Bleasel MD, et al. Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 2000 Jun; 25(3) 227–1 Hougardy DM, Peterson GM, Bleasel MD, et al. Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 2000 Jun; 25(3) 227–1
68.
go back to reference Ettinger B, Chidambaran P, Pressman A. Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 2001 Jun; 7(6): 597–605PubMed Ettinger B, Chidambaran P, Pressman A. Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 2001 Jun; 7(6): 597–605PubMed
69.
go back to reference Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998 Jun; 27(2): 465–83PubMedCrossRef Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998 Jun; 27(2): 465–83PubMedCrossRef
70.
go back to reference Humphrey EL, Williams JH, Davie MW, et al. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 2006 May; 38(5): 652–61PubMedCrossRef Humphrey EL, Williams JH, Davie MW, et al. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 2006 May; 38(5): 652–61PubMedCrossRef
71.
go back to reference Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemical and biophysical research communications. 1997 May 8; 234(1): 137–42PubMedCrossRef Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemical and biophysical research communications. 1997 May 8; 234(1): 137–42PubMedCrossRef
72.
go back to reference Buckley KA, Fraser WD. Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. Ann Clin Biochem 2002 Nov; 39 (Pt 6): 551–6PubMedCrossRef Buckley KA, Fraser WD. Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. Ann Clin Biochem 2002 Nov; 39 (Pt 6): 551–6PubMedCrossRef
73.
go back to reference Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/ RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004 Sep; 4(3): 268–75PubMed Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/ RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004 Sep; 4(3): 268–75PubMed
74.
go back to reference Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 1983 Feb; 18(2): 155–66CrossRef Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 1983 Feb; 18(2): 155–66CrossRef
75.
go back to reference Askari A, Vignos PJ, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976 Oct; 61(4): 485–92PubMedCrossRef Askari A, Vignos PJ, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976 Oct; 61(4): 485–92PubMedCrossRef
76.
go back to reference Naim MY, Reed AM. Enzyme elevation in patients with juvenile dermatomyositis and steroid myopathy. J Rheumatol 2006 Jul; 33(7): 1392–4PubMed Naim MY, Reed AM. Enzyme elevation in patients with juvenile dermatomyositis and steroid myopathy. J Rheumatol 2006 Jul; 33(7): 1392–4PubMed
77.
go back to reference Decramer M, Stas KJ. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis 1992 Sep; 146(3): 800–2PubMed Decramer M, Stas KJ. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis 1992 Sep; 146(3): 800–2PubMed
78.
go back to reference Falduto MT, Czerwinski SM, Hickson RC. Glucocorticoid-induced muscle atrophy prevention by exercise in fast-twitch fibers. J Appl Physiol 1990 Sep; 69(3): 1058–62PubMed Falduto MT, Czerwinski SM, Hickson RC. Glucocorticoid-induced muscle atrophy prevention by exercise in fast-twitch fibers. J Appl Physiol 1990 Sep; 69(3): 1058–62PubMed
79.
go back to reference Falduto MT, Young AP, Hickson RC. Exercise interrupts ongoing glucocorticoid-induced muscle atrophy and glutamine synthetase induction. Am J Physiol 1992 Dec; 263 (6 Pt 1): E1157–63PubMed Falduto MT, Young AP, Hickson RC. Exercise interrupts ongoing glucocorticoid-induced muscle atrophy and glutamine synthetase induction. Am J Physiol 1992 Dec; 263 (6 Pt 1): E1157–63PubMed
80.
go back to reference Horber FF, Scheidegger JR, Grunig BE, et al. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab 1985 Jul; 61(1): 83–8PubMedCrossRef Horber FF, Scheidegger JR, Grunig BE, et al. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab 1985 Jul; 61(1): 83–8PubMedCrossRef
81.
go back to reference Bielefeld P. Present status of cortisone myopathy [in French]. Rev Med Interne 1996; 17(3): 255–61PubMedCrossRef Bielefeld P. Present status of cortisone myopathy [in French]. Rev Med Interne 1996; 17(3): 255–61PubMedCrossRef
82.
go back to reference Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985 Aug; 76 (2 Pt 1): 234–42PubMedCrossRef Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985 Aug; 76 (2 Pt 1): 234–42PubMedCrossRef
83.
go back to reference Hasselgren PO. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care 1999 May; 2(3): 201–5PubMedCrossRef Hasselgren PO. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care 1999 May; 2(3): 201–5PubMedCrossRef
84.
go back to reference Larsson L, Li X, Edstrom L, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med 2000 Jan; 28(1): 34–45PubMedCrossRef Larsson L, Li X, Edstrom L, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med 2000 Jan; 28(1): 34–45PubMedCrossRef
85.
go back to reference Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983 Jul 7; 309(1): 21–4PubMedCrossRef Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983 Jul 7; 309(1): 21–4PubMedCrossRef
86.
go back to reference Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001 Jun 1; 153(11): 1089–93PubMedCrossRef Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001 Jun 1; 153(11): 1089–93PubMedCrossRef
87.
go back to reference Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991 May 1; 114(9): 735–40PubMed Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991 May 1; 114(9): 735–40PubMed
88.
go back to reference Kos-Kudla B, Ciesielska-Kopacz N, Ostrowska Z, et al. Adrenal cortex function in asthmatic patients following the discontinuation of chronic therapy with systemic glucocorticosteroids. J Clin Pharm Ther 2003 Apr; 28(2): 103–8PubMedCrossRef Kos-Kudla B, Ciesielska-Kopacz N, Ostrowska Z, et al. Adrenal cortex function in asthmatic patients following the discontinuation of chronic therapy with systemic glucocorticosteroids. J Clin Pharm Ther 2003 Apr; 28(2): 103–8PubMedCrossRef
89.
go back to reference Pullar T, Sturrock RD. Adrenal response in rheumatoid arthritis treated with long-term steroids. Eur J Rheumatol Inflamm 1983; 6(2): 187–91PubMed Pullar T, Sturrock RD. Adrenal response in rheumatoid arthritis treated with long-term steroids. Eur J Rheumatol Inflamm 1983; 6(2): 187–91PubMed
90.
go back to reference Downie WW, Dixon JS, Lowe JR, et al. Adrenocortical suppression by synthetic corticosteroid drugs: a comparative study of prednisolone and betamethasone. Br J Clin Pharmacol 1978 Nov; 6(5): 397–9PubMedCrossRef Downie WW, Dixon JS, Lowe JR, et al. Adrenocortical suppression by synthetic corticosteroid drugs: a comparative study of prednisolone and betamethasone. Br J Clin Pharmacol 1978 Nov; 6(5): 397–9PubMedCrossRef
91.
go back to reference Salassa RM, Bennett WA, Keating Jr FR, et al. Postoperative adrenal cortical insufficiency; occurrence in patients previously treated with cortisone. JAMA 1953 Aug 15; 152(16): 1509–15 879CrossRef Salassa RM, Bennett WA, Keating Jr FR, et al. Postoperative adrenal cortical insufficiency; occurrence in patients previously treated with cortisone. JAMA 1953 Aug 15; 152(16): 1509–15 879CrossRef
92.
go back to reference Streck WF, Lockwood DH. Pituitary adrenal recovery following short-term suppression with corticosteroids. Am J Med 1979 Jun; 66(6): 910–4PubMedCrossRef Streck WF, Lockwood DH. Pituitary adrenal recovery following short-term suppression with corticosteroids. Am J Med 1979 Jun; 66(6): 910–4PubMedCrossRef
93.
go back to reference Henzen C, Suter A, Lerch E, et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000 Feb 12; 355(9203): 542–5PubMedCrossRef Henzen C, Suter A, Lerch E, et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000 Feb 12; 355(9203): 542–5PubMedCrossRef
94.
go back to reference Claman HN. Glucocorticosteroids II: the clinical responses. Hosp Pract (Off Ed) 1983 Jul; 18(7): 143–6, 149–51 Claman HN. Glucocorticosteroids II: the clinical responses. Hosp Pract (Off Ed) 1983 Jul; 18(7): 143–6, 149–51
95.
go back to reference Spiegel RJ, Vigersky RA, Oliff AI, et al. Adrenal suppression after short-term corticosteroid therapy. Lancet 1979 Mar 24; 1(8117): 630–3PubMedCrossRef Spiegel RJ, Vigersky RA, Oliff AI, et al. Adrenal suppression after short-term corticosteroid therapy. Lancet 1979 Mar 24; 1(8117): 630–3PubMedCrossRef
96.
go back to reference Hummel M, Warnecke H, Schuler S, et al. Risk of adrenal cortex insufficiency following heart transplantation [in German]. Klin Wochenschr 1991 Apr 4; 69(6): 269–73PubMedCrossRef Hummel M, Warnecke H, Schuler S, et al. Risk of adrenal cortex insufficiency following heart transplantation [in German]. Klin Wochenschr 1991 Apr 4; 69(6): 269–73PubMedCrossRef
97.
go back to reference Walsh JP, Dayan CM. Role of biochemical assessment in management of corticosteroid withdrawal. Ann Clin Biochem 2000 May; 37 (Pt 3): 279–88PubMedCrossRef Walsh JP, Dayan CM. Role of biochemical assessment in management of corticosteroid withdrawal. Ann Clin Biochem 2000 May; 37 (Pt 3): 279–88PubMedCrossRef
98.
go back to reference Tordjman K, Jaffe A, Trostanetsky Y, et al. Low-dose (1 micro-gram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. Clin Endocrinol (Oxf) 2000 May; 52(5): 633–40CrossRef Tordjman K, Jaffe A, Trostanetsky Y, et al. Low-dose (1 micro-gram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. Clin Endocrinol (Oxf) 2000 May; 52(5): 633–40CrossRef
99.
go back to reference Suliman AM, Smith TP, Labib M, et al. The low-dose ACTH test does not provide a useful assessment of the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency. Clin Endocrinol (Oxf). 2002 Apr; 56(4): 533–9CrossRef Suliman AM, Smith TP, Labib M, et al. The low-dose ACTH test does not provide a useful assessment of the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency. Clin Endocrinol (Oxf). 2002 Apr; 56(4): 533–9CrossRef
100.
go back to reference Rasmuson S, Olsson T, Hagg E. A low dose ACTH test to assess the function of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf). 1996 Feb; 44(2): 151–6CrossRef Rasmuson S, Olsson T, Hagg E. A low dose ACTH test to assess the function of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf). 1996 Feb; 44(2): 151–6CrossRef
101.
go back to reference Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med 2003 Aug 5; 139(3): 194–204PubMed Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med 2003 Aug 5; 139(3): 194–204PubMed
102.
go back to reference Jerjes WK, Cleare AJ, Wood PJ, et al. Assessment of subtle changes in glucocorticoid negative feedback using prednisolone: comparison of salivary free cortisol and urinary cortisol metabolites as endpoints. Clin Chim Acta 2006 Feb; 364(1–2): 279–86PubMedCrossRef Jerjes WK, Cleare AJ, Wood PJ, et al. Assessment of subtle changes in glucocorticoid negative feedback using prednisolone: comparison of salivary free cortisol and urinary cortisol metabolites as endpoints. Clin Chim Acta 2006 Feb; 364(1–2): 279–86PubMedCrossRef
103.
go back to reference Gozansky WS, Lynn JS, Laudenslager ML, et al. Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic—pituitary—adrenal axis activity. Clin Endocrinol (Oxf) 2005 Sep; 63(3): 336–41CrossRef Gozansky WS, Lynn JS, Laudenslager ML, et al. Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic—pituitary—adrenal axis activity. Clin Endocrinol (Oxf) 2005 Sep; 63(3): 336–41CrossRef
104.
go back to reference Axelrod L. Perioperative management of patients treated with glucocorticoids. Endocrinol Metab Clin North Am 2003 Jun; 32(2): 367–83PubMedCrossRef Axelrod L. Perioperative management of patients treated with glucocorticoids. Endocrinol Metab Clin North Am 2003 Jun; 32(2): 367–83PubMedCrossRef
105.
go back to reference Salem M, Tainsh Jr RE, Bromberg J, et al. Perioperative glucocorticoid coverage: a reassessment 42 years after emergence of a problem. Ann Surg 1994 Apr; 219(4): 416–25PubMedCrossRef Salem M, Tainsh Jr RE, Bromberg J, et al. Perioperative glucocorticoid coverage: a reassessment 42 years after emergence of a problem. Ann Surg 1994 Apr; 219(4): 416–25PubMedCrossRef
106.
107.
108.
go back to reference Staples PJ, Gerding DN, Decker JL, et al. Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 1974 Jan–Feb; 17(1): 1–10PubMedCrossRef Staples PJ, Gerding DN, Decker JL, et al. Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 1974 Jan–Feb; 17(1): 1–10PubMedCrossRef
109.
go back to reference Myerowitz RL, Medeiros AA, O’Brien TF. Bacterial infection in renal homotransplant recipients: a study of fifty-three bacteremic episodes. Am J Med 1972 Sep; 53(3): 308–14PubMedCrossRef Myerowitz RL, Medeiros AA, O’Brien TF. Bacterial infection in renal homotransplant recipients: a study of fifty-three bacteremic episodes. Am J Med 1972 Sep; 53(3): 308–14PubMedCrossRef
110.
go back to reference Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989 Nov–Dec; 11(6): 954–63PubMedCrossRef Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989 Nov–Dec; 11(6): 954–63PubMedCrossRef
111.
go back to reference Mok MY, Lo Y, Chan TM, et al. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. J Rheumatol 2005 Apr; 32(4): 609–15PubMed Mok MY, Lo Y, Chan TM, et al. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. J Rheumatol 2005 Apr; 32(4): 609–15PubMed
112.
go back to reference Gaitonde S, Pathan E, Sule A, et al. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 2002 Mar; 61(3): 251–3PubMedCrossRef Gaitonde S, Pathan E, Sule A, et al. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 2002 Mar; 61(3): 251–3PubMedCrossRef
113.
go back to reference Hernandez-Cruz B, Ponce-de-Leon-Rosales S, Sifuentes-Osornio J, et al. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases: a case-control study. Clin Exp Rheumatol 1999 Jan–Feb; 17(1): 81–7PubMed Hernandez-Cruz B, Ponce-de-Leon-Rosales S, Sifuentes-Osornio J, et al. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases: a case-control study. Clin Exp Rheumatol 1999 Jan–Feb; 17(1): 81–7PubMed
114.
go back to reference Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006 Feb 15; 55(1): 19–26PubMedCrossRef Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006 Feb 15; 55(1): 19–26PubMedCrossRef
115.
go back to reference Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000 Jun 9; 49 (RR-6): 1–51 Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000 Jun 9; 49 (RR-6): 1–51
116.
go back to reference American Thoracic Society. Medical Section of the American Lung Association: treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986 Aug; 134(2): 355–63 American Thoracic Society. Medical Section of the American Lung Association: treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986 Aug; 134(2): 355–63
117.
go back to reference Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007 Mar 6; 146(5): 340–54PubMed Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007 Mar 6; 146(5): 340–54PubMed
118.
go back to reference Winston DJ, Ho WG, Schiffman G, et al. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med 1983 Sep; 143(9): 1735–7PubMedCrossRef Winston DJ, Ho WG, Schiffman G, et al. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med 1983 Sep; 143(9): 1735–7PubMedCrossRef
119.
go back to reference Spika JS, Halsey NA, Fish AJ, et al. Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome. Pediatrics 1982 Feb; 69(2): 219–23PubMed Spika JS, Halsey NA, Fish AJ, et al. Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome. Pediatrics 1982 Feb; 69(2): 219–23PubMed
120.
go back to reference Patel H, Macarthur C, Johnson D. Recent corticosteroid use and the risk of complicated varicella in otherwise immunocom-petent children. Arch Pediatr Adolesc Med 1996 Apr; 150(4): 409–14PubMedCrossRef Patel H, Macarthur C, Johnson D. Recent corticosteroid use and the risk of complicated varicella in otherwise immunocom-petent children. Arch Pediatr Adolesc Med 1996 Apr; 150(4): 409–14PubMedCrossRef
121.
go back to reference Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics 1993 Aug; 92(2): 223–8PubMed Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics 1993 Aug; 92(2): 223–8PubMed
122.
go back to reference Adhami N, Arabi Y, Raees A, et al. Effect of corticosteroids on adult varicella pneumonia: cohort study and literature review. Respirology 2006 Jul; 11(4): 437–41PubMedCrossRef Adhami N, Arabi Y, Raees A, et al. Effect of corticosteroids on adult varicella pneumonia: cohort study and literature review. Respirology 2006 Jul; 11(4): 437–41PubMedCrossRef
123.
go back to reference Satoh N, Abe T, Nakajima A, et al. Recurrent varicella-zoster virus retinitis in a patient treated with systemic corticosteroids: ocular immunology and inflammation. 1998 Sep; 6(3): 185–8CrossRef Satoh N, Abe T, Nakajima A, et al. Recurrent varicella-zoster virus retinitis in a patient treated with systemic corticosteroids: ocular immunology and inflammation. 1998 Sep; 6(3): 185–8CrossRef
124.
go back to reference Salisbury DM, Begg NT. Varicella: immunisation against infectious diseases. London: HMSO, 1996: 251–61 Salisbury DM, Begg NT. Varicella: immunisation against infectious diseases. London: HMSO, 1996: 251–61
125.
go back to reference Feher MD, Simms JP, Lant AF. History of chicken pox and steroid cards: a new warning? BMJ 1996 Mar 2; 312(7030): 542–61 Feher MD, Simms JP, Lant AF. History of chicken pox and steroid cards: a new warning? BMJ 1996 Mar 2; 312(7030): 542–61
126.
go back to reference Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002 Jun; 3(6): 333–40PubMedCrossRef Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002 Jun; 3(6): 333–40PubMedCrossRef
127.
go back to reference Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 1999 Apr; 21(4): 253–61PubMedCrossRef Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 1999 Apr; 21(4): 253–61PubMedCrossRef
128.
go back to reference Tur-Kaspa R, Burk RD, Shaul Y, et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 1986 Mar; 83(6): 1627–31PubMedCrossRef Tur-Kaspa R, Burk RD, Shaul Y, et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 1986 Mar; 83(6): 1627–31PubMedCrossRef
129.
go back to reference Vassiliadis T, Garipidou V, Tziomalos K, et al. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy: a prospective case series. Am J Hematol 2005 Nov; 80(3): 197–203PubMedCrossRef Vassiliadis T, Garipidou V, Tziomalos K, et al. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy: a prospective case series. Am J Hematol 2005 Nov; 80(3): 197–203PubMedCrossRef
130.
go back to reference Hanania NA, Sockrider M, Castro M, et al. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J Allergy Clin Immunol 2004 Apr; 113(4): 717–24PubMedCrossRef Hanania NA, Sockrider M, Castro M, et al. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J Allergy Clin Immunol 2004 Apr; 113(4): 717–24PubMedCrossRef
131.
go back to reference Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003 Nov 29; 362(9398): 1828–38PubMedCrossRef Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003 Nov 29; 362(9398): 1828–38PubMedCrossRef
132.
go back to reference O’Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994 Apr; 12(4): 827–34PubMed O’Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994 Apr; 12(4): 827–34PubMed
133.
go back to reference Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002 Dec 15; 100(13): 4358–66PubMedCrossRef Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002 Dec 15; 100(13): 4358–66PubMedCrossRef
134.
go back to reference Iriya SM, Capelozzi VL, Calich I, et al. Causes of death in patients with systemic lupus erythematosus in Sao Paulo, Brazil: a study of 113 autopsies. Arch Intern Med 2001 Jun25; 161(12): 1557PubMedCrossRef Iriya SM, Capelozzi VL, Calich I, et al. Causes of death in patients with systemic lupus erythematosus in Sao Paulo, Brazil: a study of 113 autopsies. Arch Intern Med 2001 Jun25; 161(12): 1557PubMedCrossRef
135.
go back to reference Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002 Mar; 21(3): 209–11PubMedCrossRef Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002 Mar; 21(3): 209–11PubMedCrossRef
136.
go back to reference Kontoyiannis DP, Vaziri I, Hanna HA, et al. Risk Factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001 Nov 15; 33(10): 1676–81PubMedCrossRef Kontoyiannis DP, Vaziri I, Hanna HA, et al. Risk Factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001 Nov 15; 33(10): 1676–81PubMedCrossRef
137.
go back to reference Gumbo T, Isada CM, Hall G, et al. Candida glabrata Fungemia: clinical features of 139 patients. Medicine 1999 Jul; 78(4): 220–7PubMedCrossRef Gumbo T, Isada CM, Hall G, et al. Candida glabrata Fungemia: clinical features of 139 patients. Medicine 1999 Jul; 78(4): 220–7PubMedCrossRef
138.
go back to reference Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996 Jan; 71(1): 5–13PubMedCrossRef Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996 Jan; 71(1): 5–13PubMedCrossRef
139.
go back to reference Gluck T, Geerdes-Fenge HF, Straub RH, et al. Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 2000 Jul–Aug; 28(4): 227–30PubMedCrossRef Gluck T, Geerdes-Fenge HF, Straub RH, et al. Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 2000 Jul–Aug; 28(4): 227–30PubMedCrossRef
140.
go back to reference Davidson RA, Fletcher RH, Chapman LE. Risk factors for strongyloidiasis: a case-control study. Arch Intern Med 1984 Feb; 144(2): 321–4PubMedCrossRef Davidson RA, Fletcher RH, Chapman LE. Risk factors for strongyloidiasis: a case-control study. Arch Intern Med 1984 Feb; 144(2): 321–4PubMedCrossRef
141.
go back to reference Nucci M, Portugal R, Pulcheri W, et al. Strongyloidiasis in patients with hematologic malignancies. Clin Infect Dis 1995 Sep; 21(3): 675–7PubMedCrossRef Nucci M, Portugal R, Pulcheri W, et al. Strongyloidiasis in patients with hematologic malignancies. Clin Infect Dis 1995 Sep; 21(3): 675–7PubMedCrossRef
142.
go back to reference Fardet L, Genereau T, Poirot JL, et al. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect 2007 Jan; 54(1): 18–27PubMedCrossRef Fardet L, Genereau T, Poirot JL, et al. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect 2007 Jan; 54(1): 18–27PubMedCrossRef
143.
go back to reference Centers for Disease Control and Prevention, Infectious Disease Society of America, Transplantation ASoBaM. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49 (RR-10): 1–125, CE1-7 Centers for Disease Control and Prevention, Infectious Disease Society of America, Transplantation ASoBaM. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49 (RR-10): 1–125, CE1-7
144.
go back to reference Carpenter Jr WT, Gruen PH. Cortisol’s effects on human mental functioning. J Clin Psychopharmacol 1982 Apr; 2(2): 91–101PubMedCrossRef Carpenter Jr WT, Gruen PH. Cortisol’s effects on human mental functioning. J Clin Psychopharmacol 1982 Apr; 2(2): 91–101PubMedCrossRef
145.
go back to reference Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment: a prospective study. Psychoneuroendocrinology 1996 Jan; 21(1): 25–31PubMedCrossRef Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment: a prospective study. Psychoneuroendocrinology 1996 Jan; 21(1): 25–31PubMedCrossRef
146.
go back to reference Fauchais AL, Boivin V, Hachulla E, et al. Psychiatric complications of corticoid therapy in the elderly over 65 years of age treated for Horton disease [in French]. Rev Med Interne 2002 Oct; 23(10): 828–33PubMedCrossRef Fauchais AL, Boivin V, Hachulla E, et al. Psychiatric complications of corticoid therapy in the elderly over 65 years of age treated for Horton disease [in French]. Rev Med Interne 2002 Oct; 23(10): 828–33PubMedCrossRef
147.
go back to reference Hall RC, Popkin MK, Stickney SK, et al. Presentation of the steroid psychoses. J Nerv Ment Dis 1979 Apr; 167(4): 229–36PubMedCrossRef Hall RC, Popkin MK, Stickney SK, et al. Presentation of the steroid psychoses. J Nerv Ment Dis 1979 Apr; 167(4): 229–36PubMedCrossRef
148.
go back to reference Brown ES, Khan DA, Nejtek VA. The psychiatric side effects of corticosteroids. Ann Allergy Asthma Immunol 1999 Dec; 83 (6 Pt 1): 495–503PubMedCrossRef Brown ES, Khan DA, Nejtek VA. The psychiatric side effects of corticosteroids. Ann Allergy Asthma Immunol 1999 Dec; 83 (6 Pt 1): 495–503PubMedCrossRef
149.
go back to reference Glaser GH. Psychotic reactions induced by corticotropin (AC-TH) cortisone. Psychosom Med 1953 Jul–Aug; 15(4): 280–91PubMed Glaser GH. Psychotic reactions induced by corticotropin (AC-TH) cortisone. Psychosom Med 1953 Jul–Aug; 15(4): 280–91PubMed
150.
go back to reference Satel SL. Mental status changes in children receiving glucocorticoids: review of the literature. Clin Pediatr (Phila) 1990 Jul; 29(7): 383–8CrossRef Satel SL. Mental status changes in children receiving glucocorticoids: review of the literature. Clin Pediatr (Phila) 1990 Jul; 29(7): 383–8CrossRef
151.
go back to reference Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972 Sep–Oct; 13(5): 694–8 Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972 Sep–Oct; 13(5): 694–8
152.
go back to reference Wolkowitz OM. Long-lasting behavioral changes following prednisone withdrawal. JAMA 1989 Mar 24–31; 261(12): 1731–2PubMedCrossRef Wolkowitz OM. Long-lasting behavioral changes following prednisone withdrawal. JAMA 1989 Mar 24–31; 261(12): 1731–2PubMedCrossRef
153.
go back to reference Venkatarangam SH, Kutcher SP, Notkin RM. Secondary mania with steroid withdrawal. Can J Psychiatry 1988 Oct; 33(7): 631–2PubMed Venkatarangam SH, Kutcher SP, Notkin RM. Secondary mania with steroid withdrawal. Can J Psychiatry 1988 Oct; 33(7): 631–2PubMed
154.
go back to reference Campbell KM, Schubert DS. Delirium after cessation of glucocorticoid therapy. Gen Hosp Psychiatry 1991 Jul; 13(4): 270–2PubMedCrossRef Campbell KM, Schubert DS. Delirium after cessation of glucocorticoid therapy. Gen Hosp Psychiatry 1991 Jul; 13(4): 270–2PubMedCrossRef
155.
go back to reference Klein JF. Adverse psychiatric effects of systemic glucocorticoid therapy. Am Fam Physician 1992 Nov; 46(5): 1469–74PubMed Klein JF. Adverse psychiatric effects of systemic glucocorticoid therapy. Am Fam Physician 1992 Nov; 46(5): 1469–74PubMed
156.
go back to reference Urban Jr RC, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986 Sep–Oct; 31(2): 102–10PubMedCrossRef Urban Jr RC, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986 Sep–Oct; 31(2): 102–10PubMedCrossRef
157.
go back to reference Garbe E, LeLorier J, Boivin JF, et al. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997 Oct 4; 350(9083): 979–82PubMedCrossRef Garbe E, LeLorier J, Boivin JF, et al. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997 Oct 4; 350(9083): 979–82PubMedCrossRef
158.
go back to reference Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998 Aug 12; 280(6): 539–43PubMedCrossRef Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998 Aug 12; 280(6): 539–43PubMedCrossRef
159.
go back to reference Nishigori H, Hayashi R, Lee JW, et al. Preventive effect of ascorbic acid against glucocorticoid-induced cataract formation of developing chick embryos. Exp Eye Res 1985 Mar; 40(3): 445–51PubMedCrossRef Nishigori H, Hayashi R, Lee JW, et al. Preventive effect of ascorbic acid against glucocorticoid-induced cataract formation of developing chick embryos. Exp Eye Res 1985 Mar; 40(3): 445–51PubMedCrossRef
160.
go back to reference Nagata M, Hikida M, Mibu H, et al. Effect of ascorbic acid 2-O-alpha-glucoside on hydrocortisone-induced cataract formation in developing chick embryos: II. Influence on glutathione and lipid peroxide contents in the lens. J Ocul Pharmacol 1994 Fall; 10(3): 537–42 Nagata M, Hikida M, Mibu H, et al. Effect of ascorbic acid 2-O-alpha-glucoside on hydrocortisone-induced cataract formation in developing chick embryos: II. Influence on glutathione and lipid peroxide contents in the lens. J Ocul Pharmacol 1994 Fall; 10(3): 537–42
161.
go back to reference Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999 Dec; 15(6): 439–50PubMedCrossRef Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999 Dec; 15(6): 439–50PubMedCrossRef
162.
go back to reference Tripathi RC, Kipp MA, Tripathi BJ, et al. Ocular toxicity of prednisone in pediatric patients with inflammatory bowel disease. Lens Eye Toxic Res 1992; 9(3–4): 469–82PubMed Tripathi RC, Kipp MA, Tripathi BJ, et al. Ocular toxicity of prednisone in pediatric patients with inflammatory bowel disease. Lens Eye Toxic Res 1992; 9(3–4): 469–82PubMed
163.
go back to reference Spaeth GL, Rodrigues MM, Weinreb S. Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects. Trans Am Ophthalmol Soc 1977; 75: 353–81 Spaeth GL, Rodrigues MM, Weinreb S. Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects. Trans Am Ophthalmol Soc 1977; 75: 353–81
164.
go back to reference Katz HI, Prawer SE, Mooney JJ, et al. Preatrophy: covert sign of thinned skin. J Am Acad Dermatol 1989 May; 20 (5 Pt 1): 731–5PubMedCrossRef Katz HI, Prawer SE, Mooney JJ, et al. Preatrophy: covert sign of thinned skin. J Am Acad Dermatol 1989 May; 20 (5 Pt 1): 731–5PubMedCrossRef
165.
go back to reference Sutton RD, Benedek TG, Edwards GA. Aseptic Bone Necrosis and Corticosteroid Therapy. Arch Intern Med 1963 Oct; 112: 594–602PubMedCrossRef Sutton RD, Benedek TG, Edwards GA. Aseptic Bone Necrosis and Corticosteroid Therapy. Arch Intern Med 1963 Oct; 112: 594–602PubMedCrossRef
166.
go back to reference Fisher DE. The role of fat embolism in the etiology of corticosteroid-induced avascular necrosis: clinical and experimental results. Clin Orthop Relat Res 1978 Jan–Feb; 130: 68–80PubMed Fisher DE. The role of fat embolism in the etiology of corticosteroid-induced avascular necrosis: clinical and experimental results. Clin Orthop Relat Res 1978 Jan–Feb; 130: 68–80PubMed
167.
go back to reference Richards JM, Santiago SM, Klaustermeyer WB. Aseptic necrosis of the femoral head in corticosteroid-treated pulmonary disease. Arch Intern Med 1980 Nov; 140(11): 1473–5PubMedCrossRef Richards JM, Santiago SM, Klaustermeyer WB. Aseptic necrosis of the femoral head in corticosteroid-treated pulmonary disease. Arch Intern Med 1980 Nov; 140(11): 1473–5PubMedCrossRef
168.
go back to reference Bomelburg T, von Lengerke HJ, Ritter J. Aseptic osteonecroses in the treatment of childhood acute leukaemias. Eur J Pediatr 1989 Oct; 149(1): 20–3PubMedCrossRef Bomelburg T, von Lengerke HJ, Ritter J. Aseptic osteonecroses in the treatment of childhood acute leukaemias. Eur J Pediatr 1989 Oct; 149(1): 20–3PubMedCrossRef
169.
go back to reference Weiner ES, Abeles M. Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. J Rheumatol 1989 May; 16(5): 604–8PubMed Weiner ES, Abeles M. Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. J Rheumatol 1989 May; 16(5): 604–8PubMed
170.
go back to reference Haajanen J, Saarinen O, Laasonen L, et al. Steroid treatment and aseptic necrosis of the femoral head in renal transplant recipients. Transplant Proc 1984 Oct; 16(5): 1316–9PubMed Haajanen J, Saarinen O, Laasonen L, et al. Steroid treatment and aseptic necrosis of the femoral head in renal transplant recipients. Transplant Proc 1984 Oct; 16(5): 1316–9PubMed
171.
go back to reference Patton PR, Pfaff WW. Aseptic bone necrosis after renal transplantation. Surgery 1988 Jan; 103(1): 63–8PubMed Patton PR, Pfaff WW. Aseptic bone necrosis after renal transplantation. Surgery 1988 Jan; 103(1): 63–8PubMed
172.
go back to reference Yoshizawa Y, Ogasa S, Izaki S, et al. Corticosteroid-induced pancreatitis in patients with autoimmune bullous disease: case report and prospective study. Dermatology 1999; 198(3): 304–6PubMedCrossRef Yoshizawa Y, Ogasa S, Izaki S, et al. Corticosteroid-induced pancreatitis in patients with autoimmune bullous disease: case report and prospective study. Dermatology 1999; 198(3): 304–6PubMedCrossRef
173.
go back to reference Keefe M, Munro F. Acute pancreatitis: a fatal complication of treatment of bullous pemphigoid with systemic corticosteroids. Dermatologica 1989; 179(2): 73–5PubMedCrossRef Keefe M, Munro F. Acute pancreatitis: a fatal complication of treatment of bullous pemphigoid with systemic corticosteroids. Dermatologica 1989; 179(2): 73–5PubMedCrossRef
174.
go back to reference Jain R, Ramanan SV. Iatrogenic pancreatitis: a fatal complication in the induction therapy for acute lymphocytic leukemia. Arch Intern Med 1978 Nov; 138(11): 1726PubMedCrossRef Jain R, Ramanan SV. Iatrogenic pancreatitis: a fatal complication in the induction therapy for acute lymphocytic leukemia. Arch Intern Med 1978 Nov; 138(11): 1726PubMedCrossRef
175.
go back to reference Oppenheimer EH, Boitnott JK. Pancreatitis in children following adrenal cortico-steroid therapy. Bull Johns Hopkins Hosp 1960 Dec; 107: 297–306 881PubMed Oppenheimer EH, Boitnott JK. Pancreatitis in children following adrenal cortico-steroid therapy. Bull Johns Hopkins Hosp 1960 Dec; 107: 297–306 881PubMed
176.
go back to reference Liddle GW. Effects of anti-inflammatory steroids on electrolvte metabolism. Ann N Y Acad Sci 1959 Oct 14; 82: 854–67PubMedCrossRef Liddle GW. Effects of anti-inflammatory steroids on electrolvte metabolism. Ann N Y Acad Sci 1959 Oct 14; 82: 854–67PubMedCrossRef
177.
go back to reference Bartter FC. The role of aldosterone in normal homeostasis and in certain disease states. Metabolism 1956 Jul; 5(4): 369–83PubMed Bartter FC. The role of aldosterone in normal homeostasis and in certain disease states. Metabolism 1956 Jul; 5(4): 369–83PubMed
178.
go back to reference Nabarro JD, Stewart JS, Walker G. Clinical and metabolic effects of prednisone. Lancet 1955 Nov 12; 269(6898): 993–8PubMedCrossRef Nabarro JD, Stewart JS, Walker G. Clinical and metabolic effects of prednisone. Lancet 1955 Nov 12; 269(6898): 993–8PubMedCrossRef
179.
go back to reference Bunim JJ, Pechet MM, Bollet AJ. Studies on metacortandralone and metacortandracin in rheumatoid arthritis; antirheumatic potency, metabolic effects, and hormonal properties. JAMA 1955 Jan 22; 157(4): 311–8CrossRef Bunim JJ, Pechet MM, Bollet AJ. Studies on metacortandralone and metacortandracin in rheumatoid arthritis; antirheumatic potency, metabolic effects, and hormonal properties. JAMA 1955 Jan 22; 157(4): 311–8CrossRef
180.
go back to reference Pechet MM BF. Studies with a new series of steroids metacordracin and metacortandralone [letter]. J Clin Endocrinol Metab 1955; 15: 851 Pechet MM BF. Studies with a new series of steroids metacordracin and metacortandralone [letter]. J Clin Endocrinol Metab 1955; 15: 851
181.
go back to reference Thorn GW, Renold AE, Morse WI, et al. Highly potent adrenal cortical steroids: structure and biologic activity. Ann Intern Med 1955 Nov; 43(5): 979–1000PubMed Thorn GW, Renold AE, Morse WI, et al. Highly potent adrenal cortical steroids: structure and biologic activity. Ann Intern Med 1955 Nov; 43(5): 979–1000PubMed
182.
go back to reference Morris GC, Egan JG, Keston Jones M. Hypokalaemic paralysis induced by bolus prednisolone in Graves’ disease. Aust N Z J Med 1992 Jun; 22(3): 312PubMedCrossRef Morris GC, Egan JG, Keston Jones M. Hypokalaemic paralysis induced by bolus prednisolone in Graves’ disease. Aust N Z J Med 1992 Jun; 22(3): 312PubMedCrossRef
183.
go back to reference Ramsahoye BH, Davies SV, el-Gaylani N, et al. The miner-alocorticoid effects of high dose hydrocortisone. BMJ 1995 Mar 11; 310(6980): 656–7PubMedCrossRef Ramsahoye BH, Davies SV, el-Gaylani N, et al. The miner-alocorticoid effects of high dose hydrocortisone. BMJ 1995 Mar 11; 310(6980): 656–7PubMedCrossRef
184.
go back to reference Yu EC, Wong SN, Yeung CY. Encephalopathy associated with steroid treated nephrotic syndrome. Int J Pediatr Nephrol 1987 Jul–Sep; 8(3): 135–46PubMed Yu EC, Wong SN, Yeung CY. Encephalopathy associated with steroid treated nephrotic syndrome. Int J Pediatr Nephrol 1987 Jul–Sep; 8(3): 135–46PubMed
185.
go back to reference Rosenbach Y, Zahavi I, Rachmal A, et al. Severe hypokalemia after budesonide treatment for Crohn’s disease. J Pediatr Gastroenterol Nutr 1997 Mar; 24(3): 352–5PubMedCrossRef Rosenbach Y, Zahavi I, Rachmal A, et al. Severe hypokalemia after budesonide treatment for Crohn’s disease. J Pediatr Gastroenterol Nutr 1997 Mar; 24(3): 352–5PubMedCrossRef
186.
go back to reference Lieber IH, Stoneburner SD, Floyd M, et al. Potassium-wasting nephropathy secondary to chemotherapy simulating Bartter’s syndrome. Cancer 1984 Sep 1; 54(5): 808–10PubMedCrossRef Lieber IH, Stoneburner SD, Floyd M, et al. Potassium-wasting nephropathy secondary to chemotherapy simulating Bartter’s syndrome. Cancer 1984 Sep 1; 54(5): 808–10PubMedCrossRef
188.
go back to reference Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994 Jan 10; 154(1): 97–101PubMedCrossRef Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994 Jan 10; 154(1): 97–101PubMedCrossRef
189.
go back to reference Fisher JE, Smith RS, Lagrandeur R, et al. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol 1997 Dec; 90(6): 880–3PubMedCrossRef Fisher JE, Smith RS, Lagrandeur R, et al. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol 1997 Dec; 90(6): 880–3PubMedCrossRef
190.
go back to reference Feldman-Billard S, Lissak B, Kassaei R, et al. Short-term tolerance of pulse methylprednisolone therapy in patients with diabetes mellitus. Ophthalmology 2005 Mar; 112(3): 511–5PubMedCrossRef Feldman-Billard S, Lissak B, Kassaei R, et al. Short-term tolerance of pulse methylprednisolone therapy in patients with diabetes mellitus. Ophthalmology 2005 Mar; 112(3): 511–5PubMedCrossRef
191.
go back to reference Raul Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, et al. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998 Autumn; 29(3): 259–62PubMed Raul Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, et al. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998 Autumn; 29(3): 259–62PubMed
192.
go back to reference Almon RR, Dubois DC, Jin JY, et al. Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle. J Endocrinol 2005 Jan; 184(1): 219–32PubMedCrossRef Almon RR, Dubois DC, Jin JY, et al. Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle. J Endocrinol 2005 Jan; 184(1): 219–32PubMedCrossRef
193.
go back to reference Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999 May; 96(5): 513–23CrossRef Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999 May; 96(5): 513–23CrossRef
194.
go back to reference Fernandez-Miranda C, de la Calle A, Morales JM, et al. Lipoprotein abnormalities in long-term stable liver and renal transplanted patients: a comparative study. Clin Transplant 1998 Apr; 12(2): 136–41PubMed Fernandez-Miranda C, de la Calle A, Morales JM, et al. Lipoprotein abnormalities in long-term stable liver and renal transplanted patients: a comparative study. Clin Transplant 1998 Apr; 12(2): 136–41PubMed
195.
go back to reference Becker DM, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988 Nov; 85(5): 632–8PubMedCrossRef Becker DM, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988 Nov; 85(5): 632–8PubMedCrossRef
196.
go back to reference Andrews WS, Shimaoka S, Sommerauer J, et al. Steroid withdrawal after pediatric liver transplantation. Transplant Proc 1994 Feb; 26(1): 159–60PubMed Andrews WS, Shimaoka S, Sommerauer J, et al. Steroid withdrawal after pediatric liver transplantation. Transplant Proc 1994 Feb; 26(1): 159–60PubMed
197.
go back to reference McDiarmid SV, Farmer DA, Goldstein LI, et al. A randomized prospective trial of steroid withdrawal after liver transplantation. Transplantation 1995 Dec 27; 60(12): 1443–50PubMedCrossRef McDiarmid SV, Farmer DA, Goldstein LI, et al. A randomized prospective trial of steroid withdrawal after liver transplantation. Transplantation 1995 Dec 27; 60(12): 1443–50PubMedCrossRef
198.
go back to reference Punch JD, Shieck VL, Campbell DA, et al. Corticosteroid withdrawal after liver transplantation. Surgery 1995 Oct; 118(4): 783–6; discussion 6–8PubMedCrossRef Punch JD, Shieck VL, Campbell DA, et al. Corticosteroid withdrawal after liver transplantation. Surgery 1995 Oct; 118(4): 783–6; discussion 6–8PubMedCrossRef
199.
go back to reference Jefferys DB, Lessof MH, Mattock MB. Corticosteroid treatment, serum lipids and coronary artery disease. Postgrad Med J 1980 Jul; 56(657): 491–3PubMedCrossRef Jefferys DB, Lessof MH, Mattock MB. Corticosteroid treatment, serum lipids and coronary artery disease. Postgrad Med J 1980 Jul; 56(657): 491–3PubMedCrossRef
200.
go back to reference el-Shaboury AH, Hayes TM. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. BMJ 1973 Apr 14; 2(5858): 85–6PubMedCrossRef el-Shaboury AH, Hayes TM. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. BMJ 1973 Apr 14; 2(5858): 85–6PubMedCrossRef
201.
go back to reference Picado C, Deulofeu R, Lleonart R, et al. Lipid and protein metabolism in asthma: effects of diet and corticosteroid therapy. Allergy 1999 Jun; 54(6): 569–75PubMedCrossRef Picado C, Deulofeu R, Lleonart R, et al. Lipid and protein metabolism in asthma: effects of diet and corticosteroid therapy. Allergy 1999 Jun; 54(6): 569–75PubMedCrossRef
202.
go back to reference Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003 Sep; 62(9): 842–5PubMedCrossRef Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003 Sep; 62(9): 842–5PubMedCrossRef
203.
go back to reference Seipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. J Heart Lung Transplant 2004 Mar; 23(3): 317–22PubMedCrossRef Seipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. J Heart Lung Transplant 2004 Mar; 23(3): 317–22PubMedCrossRef
204.
go back to reference Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997 Nov; 56(5): 335–40PubMedCrossRef Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997 Nov; 56(5): 335–40PubMedCrossRef
205.
go back to reference Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 1998 Jul; 58(1): 2–5PubMedCrossRef Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 1998 Jul; 58(1): 2–5PubMedCrossRef
206.
go back to reference Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 1999 Sep 17; 86(3): 242–4PubMedCrossRef Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 1999 Sep 17; 86(3): 242–4PubMedCrossRef
207.
go back to reference Fraser FC, Sajoo A. Teratogenic potential of corticosteroids in humans. Teratology 1995 Jan; 51(1): 45–6PubMedCrossRef Fraser FC, Sajoo A. Teratogenic potential of corticosteroids in humans. Teratology 1995 Jan; 51(1): 45–6PubMedCrossRef
208.
go back to reference Levy R, Matitiau A, Ben Arie A, et al. Indomethacin and corticosteroids: an additive constrictive effect on the fetal ductus arteriosus. Am J Perinatol 1999; 16(8): 379–83PubMedCrossRef Levy R, Matitiau A, Ben Arie A, et al. Indomethacin and corticosteroids: an additive constrictive effect on the fetal ductus arteriosus. Am J Perinatol 1999; 16(8): 379–83PubMedCrossRef
209.
go back to reference Schatz M, Patterson R, Zeitz S, et al. Corticosteroid therapy for the pregnant asthmatic patient. JAMA 1975 Aug 18; 233(7): 804–7PubMedCrossRef Schatz M, Patterson R, Zeitz S, et al. Corticosteroid therapy for the pregnant asthmatic patient. JAMA 1975 Aug 18; 233(7): 804–7PubMedCrossRef
210.
go back to reference Aghajafari F, Murphy K, Willan A, et al. Multiple courses of antenatal corticosteroids: a systematic review and meta-analysis. Am J Obstet Gynecol 2001 Nov; 185(5): 1073–80PubMedCrossRef Aghajafari F, Murphy K, Willan A, et al. Multiple courses of antenatal corticosteroids: a systematic review and meta-analysis. Am J Obstet Gynecol 2001 Nov; 185(5): 1073–80PubMedCrossRef
211.
go back to reference Yildirim Y, Tinar S, Oner RS, et al. Gestational diabetes mellitus in patients receiving long-term corticosteroid therapy during pregnancy. J Perinat Med 2006; 34(4): 280–4PubMedCrossRef Yildirim Y, Tinar S, Oner RS, et al. Gestational diabetes mellitus in patients receiving long-term corticosteroid therapy during pregnancy. J Perinat Med 2006; 34(4): 280–4PubMedCrossRef
212.
go back to reference Abbasi S, Hirsch D, Davis J, et al. Effect of single versus multiple courses of antenatal corticosteroids on maternal and neonatal outcome. Am J Obstet Gynecol 2000 May; 182(5): 1243–9PubMedCrossRef Abbasi S, Hirsch D, Davis J, et al. Effect of single versus multiple courses of antenatal corticosteroids on maternal and neonatal outcome. Am J Obstet Gynecol 2000 May; 182(5): 1243–9PubMedCrossRef
214.
go back to reference Morrison E, Crosbie D, Capell HA. Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. Rheumatology (Oxford) 2003 Oct; 42(10): 1247–50CrossRef Morrison E, Crosbie D, Capell HA. Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. Rheumatology (Oxford) 2003 Oct; 42(10): 1247–50CrossRef
215.
go back to reference Bae SC, Corzillius M, Kuntz KM, et al. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford) 2003 Jan; 42(1): 46–53CrossRef Bae SC, Corzillius M, Kuntz KM, et al. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford) 2003 Jan; 42(1): 46–53CrossRef
216.
go back to reference Pisu M, James N, Sampsel S, et al. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology (Oxford) 2005 Jun; 44(6): 781–8CrossRef Pisu M, James N, Sampsel S, et al. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology (Oxford) 2005 Jun; 44(6): 781–8CrossRef
Metadata
Title
Corticosteroid-Induced Adverse Events in Adults
Frequency, Screening and Prevention
Authors
Dr Laurence Fardet
Abdulrhaman Kassar
Jean Cabane
Antoine Flahault
Publication date
01-10-2007
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2007
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200730100-00005

Other articles of this Issue 10/2007

Drug Safety 10/2007 Go to the issue